For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit:  www.BMSStudyConnect.com  Inclusion Criteria:  Participants with histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent select solid tumor Eligible tumor types Non-small cell lung cancer (NSCLC), Urothelial carcinoma (UC), Squamous cell carcinoma of the head and neck (SCCHN), Hepatocellular carcinoma (HCC), Microsatellite-stable colorectal carcinoma (MSS CRC), or Pancreatic ductal adenocarcinoma (PDAC) Resistant/refractory to or intolerant of existing standard therapies known to provide clinical benefit Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) Disease amenable to serial biopsy  Exclusion Criteria:  Uncontrolled or significant cardiovascular disease Known connective tissue disease such as Marfan, Ehlers-Danlos, or Loeys-Dietz syndrome Medical requirement for chronic anticoagulant or antiplatelet agents (except low-dose aspirin, which is permitted)  Other protocol-defined inclusion/exclusion criteria apply